What type of study is this?

This is a Literature Review study (also classified as: Observational).

September 10, 2025BiomedicinesOpen Access

Adjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions

View Full Paper

Ask AI

Bookmark

Adjuvant immunotherapy improves recurrence-free survival in high-risk stage IIB melanoma and reduces distant metastasis.
Pivotal trials like KEYNOTE-716 and CheckMate 76K show significant benefits with PD-1 inhibitors, although overall survival remains unconcluded.
Observational studies emphasized the importance of personalized approaches, including biomarker development and circulating tumor DNA monitoring.
Optimally selecting patients for adjuvant therapy is challenging due to potential toxicities and uncertainty about overall survival benefits.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Literature review evaluates adjuvant immunotherapy outcomes in stage IIB/IIC melanoma, highlighting key challenges. It emphasizes the role of immune checkpoint inhibitors and biomarker development.

Cite This Study

Prkačin et al. (2025) studied this question.

synapsesocial.com/papers/68c1ad6354b1d3bfb60e57fe https://doi.org/10.3390/biomedicines13081894

View Full Paper

Ask AI

Bookmark

Implication

Literature review evaluates adjuvant immunotherapy outcomes in stage IIB/IIC melanoma, highlighting key challenges. It emphasizes the role of immune checkpoint inhibitors and biomarker development.

Adjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions

Key Points

Discussion

Implication

Cite This Study

Adjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider